Erectile Dysfunction

Hesselberg worked for Immunex Corporation and the Puget Sound Blood Center.

Mr.

Hesselberg holds a B.S.

in Molecular Biology from the University of Wisconsin-Madison and a MBA from the University of Washington.

About GTx GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions.

GTx is developing ACAPODENE® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN.

GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE®.

GTx also is developing Ostarine™, a first-in-class selective androgen receptor modulator, or SARM.

GTx plans to initiate a Phase IIb Ostarine™ clinical trial for cancer cachexia by the summer of 2007.

GTx plans to initiate a Phase IIb Ostarine™ clinical trial for the treatment of chronic kidney disease and end stage renal disease muscle wasting by ...

Read more...